2025 Q4 -tulosraportti
Vain PDF
119 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
893
Myynti
Määrä
850
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 850 | - | - | ||
| 754 | - | - | ||
| 10 000 | - | - | ||
| 332 | - | - | ||
| 665 | - | - |
Ylin
1,6VWAP
Alin
1,474VaihtoMäärä
0,6 370 046
VWAP
Ylin
1,6Alin
1,474VaihtoMäärä
0,6 370 046
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 30.10.2025 | ||
2025 Q3 -tulosraportti 24.7.2025 | ||
2025 Q2 -tulosraportti 25.4.2025 | ||
2025 Q1 -tulosraportti 30.1.2025 | ||
2024 Q4 -tulosraportti 24.10.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·19.2.Is there a reason for today's increase of approximately 10%?
·19.2.I think there are 2 concrete reasons. right now. 1. generally low price compared to the potential. 2. the news on Feb. 17. needs to sink in. Not everyone reads the news as they come.
·17.2.On days when the stock looks a bit red, it can be nice to remind myself where I want to go (Bull scenario). Realistic position for NextCell by the end of 2026 – 5–7 SEK scenario After the upcoming emission, the capital structure consists of 126,392,959 shares. At a price in the range of 5–7 SEK, this corresponds to a market capitalization of approx. 630–885 mio. SEK. The starting point today is a market capitalization of around 170–200 mio. SEK, which implies that 5–7 SEK represents a 3–5× re-rating from the current level. A realistic positive scenario for 2026 can support this level, provided continued clinical and operational progress as well as reduced financial uncertainty. The first prerequisite is further clinical data from ProTrans, which confirms preservation of C-peptide and a stable safety profile. Consistent and reproducible results will reduce the clinical risk and strengthen the positioning towards a Phase 3 progression. The second prerequisite is concrete progress in the partner dialogue. This may include a regional collaboration agreement, co-development structure or other form of formalized cooperation. External industrial validation will have a direct effect on the risk premium and thus the valuation. The third prerequisite is demonstrable development in the GMP and service business via QVance. Revenue contribution and reduced cash burn will reduce the need for further capital injection and strengthen the financial profile. If these elements are realized during 2026, a market capitalization of 630–885 mio. SEK is realistic. It presupposes continued clinical progress, absence of significant safety issues, and controlled dilution. The scenario does not presuppose regulatory approval or completed Phase 3, but involves a gradual de-risking of the company's main asset. (AI has helped write the text. This is solely intended as a positive reminder of the stock's potential. )
·16.2.Does anyone have a good idea when the following will be disclosed? 1) disclosure of the new institutional investors 2) data on Protrans Repeat 3) Content of and expectations for the collaboration with Fujifilm 4) permission for GMP sale of services to Pharma via Qvanse·17.2.Valde07, are you reading the press release from Nextcell. You can find them on the left side here or on Nextcell's website. See the press release from today and from February 3rd.- ·10.2.Anyone have any thoughts on the new emission? I think that an announcement like that will create a slightly larger drop in the short term perhaps down to just over price 1 SEK, but in the long run it can be very positive, as it means that the selected investors have faith in the case.·11.2.I don't think it will mean a drop, as the shares being offered are only for selected shareholders. Hopefully for long-term investors who will help keep the price up.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
119 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19.2.Is there a reason for today's increase of approximately 10%?·19.2.I think there are 2 concrete reasons. right now. 1. generally low price compared to the potential. 2. the news on Feb. 17. needs to sink in. Not everyone reads the news as they come.
- ·17.2.On days when the stock looks a bit red, it can be nice to remind myself where I want to go (Bull scenario). Realistic position for NextCell by the end of 2026 – 5–7 SEK scenario After the upcoming emission, the capital structure consists of 126,392,959 shares. At a price in the range of 5–7 SEK, this corresponds to a market capitalization of approx. 630–885 mio. SEK. The starting point today is a market capitalization of around 170–200 mio. SEK, which implies that 5–7 SEK represents a 3–5× re-rating from the current level. A realistic positive scenario for 2026 can support this level, provided continued clinical and operational progress as well as reduced financial uncertainty. The first prerequisite is further clinical data from ProTrans, which confirms preservation of C-peptide and a stable safety profile. Consistent and reproducible results will reduce the clinical risk and strengthen the positioning towards a Phase 3 progression. The second prerequisite is concrete progress in the partner dialogue. This may include a regional collaboration agreement, co-development structure or other form of formalized cooperation. External industrial validation will have a direct effect on the risk premium and thus the valuation. The third prerequisite is demonstrable development in the GMP and service business via QVance. Revenue contribution and reduced cash burn will reduce the need for further capital injection and strengthen the financial profile. If these elements are realized during 2026, a market capitalization of 630–885 mio. SEK is realistic. It presupposes continued clinical progress, absence of significant safety issues, and controlled dilution. The scenario does not presuppose regulatory approval or completed Phase 3, but involves a gradual de-risking of the company's main asset. (AI has helped write the text. This is solely intended as a positive reminder of the stock's potential. )
- ·16.2.Does anyone have a good idea when the following will be disclosed? 1) disclosure of the new institutional investors 2) data on Protrans Repeat 3) Content of and expectations for the collaboration with Fujifilm 4) permission for GMP sale of services to Pharma via Qvanse·17.2.Valde07, are you reading the press release from Nextcell. You can find them on the left side here or on Nextcell's website. See the press release from today and from February 3rd.
- ·10.2.Anyone have any thoughts on the new emission? I think that an announcement like that will create a slightly larger drop in the short term perhaps down to just over price 1 SEK, but in the long run it can be very positive, as it means that the selected investors have faith in the case.·11.2.I don't think it will mean a drop, as the shares being offered are only for selected shareholders. Hopefully for long-term investors who will help keep the price up.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
893
Myynti
Määrä
850
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 850 | - | - | ||
| 754 | - | - | ||
| 10 000 | - | - | ||
| 332 | - | - | ||
| 665 | - | - |
Ylin
1,6VWAP
Alin
1,474VaihtoMäärä
0,6 370 046
VWAP
Ylin
1,6Alin
1,474VaihtoMäärä
0,6 370 046
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 30.10.2025 | ||
2025 Q3 -tulosraportti 24.7.2025 | ||
2025 Q2 -tulosraportti 25.4.2025 | ||
2025 Q1 -tulosraportti 30.1.2025 | ||
2024 Q4 -tulosraportti 24.10.2024 |
2025 Q4 -tulosraportti
Vain PDF
119 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 30.10.2025 | ||
2025 Q3 -tulosraportti 24.7.2025 | ||
2025 Q2 -tulosraportti 25.4.2025 | ||
2025 Q1 -tulosraportti 30.1.2025 | ||
2024 Q4 -tulosraportti 24.10.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·19.2.Is there a reason for today's increase of approximately 10%?·19.2.I think there are 2 concrete reasons. right now. 1. generally low price compared to the potential. 2. the news on Feb. 17. needs to sink in. Not everyone reads the news as they come.
- ·17.2.On days when the stock looks a bit red, it can be nice to remind myself where I want to go (Bull scenario). Realistic position for NextCell by the end of 2026 – 5–7 SEK scenario After the upcoming emission, the capital structure consists of 126,392,959 shares. At a price in the range of 5–7 SEK, this corresponds to a market capitalization of approx. 630–885 mio. SEK. The starting point today is a market capitalization of around 170–200 mio. SEK, which implies that 5–7 SEK represents a 3–5× re-rating from the current level. A realistic positive scenario for 2026 can support this level, provided continued clinical and operational progress as well as reduced financial uncertainty. The first prerequisite is further clinical data from ProTrans, which confirms preservation of C-peptide and a stable safety profile. Consistent and reproducible results will reduce the clinical risk and strengthen the positioning towards a Phase 3 progression. The second prerequisite is concrete progress in the partner dialogue. This may include a regional collaboration agreement, co-development structure or other form of formalized cooperation. External industrial validation will have a direct effect on the risk premium and thus the valuation. The third prerequisite is demonstrable development in the GMP and service business via QVance. Revenue contribution and reduced cash burn will reduce the need for further capital injection and strengthen the financial profile. If these elements are realized during 2026, a market capitalization of 630–885 mio. SEK is realistic. It presupposes continued clinical progress, absence of significant safety issues, and controlled dilution. The scenario does not presuppose regulatory approval or completed Phase 3, but involves a gradual de-risking of the company's main asset. (AI has helped write the text. This is solely intended as a positive reminder of the stock's potential. )
- ·16.2.Does anyone have a good idea when the following will be disclosed? 1) disclosure of the new institutional investors 2) data on Protrans Repeat 3) Content of and expectations for the collaboration with Fujifilm 4) permission for GMP sale of services to Pharma via Qvanse·17.2.Valde07, are you reading the press release from Nextcell. You can find them on the left side here or on Nextcell's website. See the press release from today and from February 3rd.
- ·10.2.Anyone have any thoughts on the new emission? I think that an announcement like that will create a slightly larger drop in the short term perhaps down to just over price 1 SEK, but in the long run it can be very positive, as it means that the selected investors have faith in the case.·11.2.I don't think it will mean a drop, as the shares being offered are only for selected shareholders. Hopefully for long-term investors who will help keep the price up.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
893
Myynti
Määrä
850
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 850 | - | - | ||
| 754 | - | - | ||
| 10 000 | - | - | ||
| 332 | - | - | ||
| 665 | - | - |
Ylin
1,6VWAP
Alin
1,474VaihtoMäärä
0,6 370 046
VWAP
Ylin
1,6Alin
1,474VaihtoMäärä
0,6 370 046
Välittäjätilasto
Dataa ei löytynyt